| INTRODUCTION
Carbamazepine (CBZ), an important antiepileptic drug, is widely prescribed for the treatment of epilepsy, trigeminal neuralgia, and bipolar disorder. However, it can cause serious cutaneous adverse drug reactions (ADRs), namely Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
1 SJS is characterized by skin detachment with a death rate of about 5%, whereas TEN involves more extensive epidermal detachment and with a rate of death up to 30%. 2 Substantial studies demonstrated that carbamazepine-induced SJS-TEN is strongly associated with the human leukocyte antigen B (HLA-B) *15:02 allele. protein could directly present CBZ to CD8 + T cell, triggering cytotoxic responses in the skin of patients with SJS/TEN. 4 Chung et al. 1 first reported the association of CBZ-induced SJS/TEN with HLA-B*15:02 in 2004, which was subsequently confirmed by another three groups. [5] [6] [7] Based on these studies, the US Food and Drug Administration (FDA) issued a warning alert for CBZ and recommends that genotyping of HLA-B*15:02 should be performed for patients with 'ancestry across broad areas of Asia' before the initiation of CBZ. 8 After the warning, a number of studies provided further medical evidences supporting the association were reported. [9] [10] [11] [12] [13] [14] [15] [16] Higher risk of CBZ-associated SJS/ TEN has been found in patients from certain Asian countries, such as Thailand, 9 Malaysia, 10 India, 11 and China, [12] [13] [14] [15] [16] Table 1 ). The participants were asked to submit the genotyping results and written reports in 2 weeks.
| MATERIALS AND METHODS

| Organization of the EQA
Information regarding the testing method used, the laboratory accreditation/certification status, and the quantity of samples processed each month were also requested. 
| Preparation of EQA samples
24
Cell lines were cultured in Roswell Park Memorial Institute 1640 as described previously. 25 An improved method for the extraction of genomic DNA from a large number of cells was employed. 26 The iso- 
| Data analysis
| RESULTS
| Participants and response
| HLA-B*15:02 testing performance
The participants tested a total of 370 samples, 365 of which were correctly genotyped ( Table 1 ). All failed samples were attributed to one laboratory, which was unable to detect any positive samples Of the 37 completed data sets, 36 (97.3%) analyses were found to be 'competent'. One participant (2.7%) reported more than two wrong results, and was classified as 'unacceptable', according to the criteria. Table 2 summarizes the performance and analytical characteristics of different HLA-B*15:02 testing methods. The overall testing sensitivity and specificity were both good (97.3% and 100%, respectively) in our EQA scheme; however, 1 assay showed a poor analytical sensitivity (SBH, 0%).
| Test result reporting
The EQA organizer received and evaluated 33 testing reports. Four labs did not submit the testing reports with no explanation. The mean score of the reports was 8.05 of 9, with a SD of 0.74. 
| DISCUSSION
Pharmacogenetic interrogation of known genetic variants can help the selection of the right drugs for individual patients and avoid adverse reactions. 30 Preprescription genotyping of HLA-B*15:02 allele was used for preventing CBZ-induced SJS/TEN. Here, we report the first EQA that evaluated the performance of laboratories providing HLA-B*15:02 testing service in China.
The results of the current EQA showed that most of the partic- The test report should include all necessary information to support the clinical physician for making proper therapeutic decision.
Our study showed the shortcomings of laboratory result reporting.
According to the international standard, information regarding the laboratory, patient, sample identifiers, results, methodology, and interpretation are essential. Judged by the requirements mentioned above, the general quality of reports in this study was not good. Laboratory contact information, which can be used for further consultation, was missing in nearly half of the submitted reports. One limitation of our study is that we did not evaluate the DNA extraction step of the genetic testing process. Since it was difficult to obtain enough amount of well-characterized whole blood sample, genomic DNA with desired variants was used as a surrogate
control, which has been demonstrated to perform well in a previous proficiency testing (PT) program for pharmacogenetics tests. 31 HLA-A*31:01 is another allele found to be associated with CBZ-induced hypersensitivity reactions in Caucasian and Japanese population.
32,33
We did not assess the laboratory performance for genotyping of HLA-A*31:01 because such association has not been confirmed in Chinese population and none of the laboratories routinely test this allele. In addition, next-generation sequencing has also been adopted for HLA genotyping. However, it was not employed by any of the participating laboratories. Therefore, the performance of this particular methodology was not assessed.
In summary, this report provides evidence of the good analytical performance and improvable reporting performance of laboratories offering HLA-B*15:02 testing. EQA schemes are designed to expose and address existing shortcomings of routine molecular tests and guarantee the high testing quality. To warrant appropriate treatment decisions, regular participation in EQA is required. We aim to further expand this scheme to more laboratories to improve the quality of HLA-B*15:02 genotyping.
